Effect of Growth Factor on the Phenotype of Subpopulations and on the Kinetics of CD34⁺ Cells in the Peripheral Blood and in Grafts of Peripheral Stem Cells in Patients with Non-Hodgkin’s Lymphoma Indicated for Autologous Peripheral Blood Stem Cell Transplantation


Authors: M. Klabusay 1;  D. Lysák 2;  V. Hrabčáková 1;  M. Navrátil 1;  P. Čoupek 3;  J. Mayer 1
Authors‘ workplace: Interní hematoonkologická klinika FN, Brno 1;  Hematoonkologické oddělení FN, Plzeň 2;  Česká geologická služba 3
Published in: Čas. Lék. čes. 2008; 147: 319-324
Category: Original Article

Overview

Background.
Peripheral blood stem cells are the preferred source for transplantation of hematopoiesis in patients with non-Hodgkin’s lymphoma. Application of hematopoietic growth factors is a part of the mobilization chemotherapy regimen. Time overlap of the highest leukocyte and CD34⁺ cell count is required for optimal graft collection. Authors analyzed the effect of two growth factors (leridistim and filgrastim) on the kinetics and phenotype of CD34⁺ cells in patients with non-Hodgkin’s lymphoma indicated for autologous peripheral blood stem cell transplantation.

Methods and Results.
Authors analyzed phenotype of CD34⁺ cell subpopulations and their kinetics in peripheral blood and leukapheresis products by flow cytometry during mobilization and graft collection. Statistically significant differences in expression of lineage-committed antigens between growth factors were found (CD3, CD5 – T-lineage, CD56 NK-lineage, CD20 for B-lineage, p < 0.05), as well as for lineage non–specific antigens (CD38, p < 0.05 and CD54, p < 0.01). The most significant divergence was observed between CD34⁺CD19⁺ subpopulations of leridistim and filgrastim stimulated blood and graft (p < 0.001).

Conclusions.
Expression of lineage-committed antigens on CD34⁺ subpopulations between two growth factors was statistically different. Kinetics of CD34⁺ cells during mobilization regimen with leridistim was not superior to filgrastim concerning the quality of graft.

Key words:
hematopoietic stem cells, transplantation, growth factors, CD34⁺ cell subpopulation, kinetics


Sources

1. Tong, J., Gianni, A. M., Siena, S. et al.: Primitive hematopoietic progenitor cells are present in peripheral blood autografts. Blood Cells, 1994, 20, s. 351–363.

2. Lozano, M. L., Ortuno, F., de Arriba, F. et al.: Effect of rhG-CSF on the mobilization of CD38 and HLA-DR subfractions of CD34+ peripheral blood progenitor cells. Ann. Hematol., 1995, 71, s. 105–110.

3. Novelli, E. M., Ramirez, M., Civin, C. I.: Biology of CD34+CD38- cells in lymphohematopoiesis. Leuk. Lymphoma, 1998, 31, s. 285–293.

4. Rusten, L. S., Jacobsen, S. E. W., Kaalhus, O. et al.: Functional differences between CD38- and DR- subfractions of CD34⁺ bone marrow cells. Blood, 1994, 5, s. 1473–1481.

5. Sakabe, H., Ohmizono, Y., Tanimukai, S. et al.: Functional differences between subpopulations of mobilized peripheral blood-derived CD34+ cells expressing different levels of HLA‑DR, CD33, CD38 and c-kit antigens. Stem Cells, 1997, 15, s. 73–81.

6. Fritsch, G., Stimpfl, M., Kurz, M. et al.: The composition of CD34 subpopulations differs between bone marrow, blood and cord blood. Bone Marrow Transplant., 1996, 17, s. 169–178.

7. Feller, N., Schuurhuis, G. J., van der Pol, M. A. et al.: High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome. Leukemia, 2003, 17, s. 68–75.

8. Pytlík, R., Trnková, M., Trněný, M.: Autologní transplantace krvetvorných buněk v České republice. Čas. Lék. čes., 2003, 142, s. 733–735.

9. Arat, M., Arslan, O., Gurman, G. et al.: The impact of granulocyte colony stimulating factor at content of donor lymphocytes collected for cellular immunotherapy. Transfus. Apheresis Sci., 2004, 30, s. 9–15.

10. Raida, L, Faber, E., Papajík, T. et al.: Ovlivňuje kvalita štěpu a aplikace filgrastimu rekonstituci krvetvorby a výsledky autologních transplantací krvetvorných kmenových buněk u nemocných s maligními lymfomy? Trans. Hemat. dnes, 2003, 9, s. 125–131.

11. Gašová, Z., Ludvíková, Z., Kučerová, I. et al.: Separace hemopoetických progenitorových buněk z periferní krve (PBPC) u pacientů s hematoonkologickými malignitami. Čas. Lék. čes., 1999, 138, s. 369–373.

12. Abegg, A. L., Vickery, L. E., Bremer, M. E. et al.: The enhanced in vitro hematopoietic activity of leridistim, a chimeric dual G-CSF and IL-3 receptor agonist. Leukemia, 2002, 16, s. 316–326.

13. Hess, D. A., Levac, K. D., Karanu, F. N. et al.: Functional analysis of human hematopoietic repopulating cells mobilized with granulocyte colony-stimulating factor alone versus granulocyte colony-stimulating factor in combination with stem cell factor. Blood, 2002, 100, s. 869–878.

14. Monahan, J. B., Hood, W. F., Welply, J. K. et al.: Bivalent binding and signaling characteristics of Leridistim, a novel chimeric dual agonist of Interleukin-3 and granulocyte colony-stimulating factor receptors. Exp. Hematol., 2001, 29, s. 416–424.

15. Farese, A. M., Casey, D. B., Smith, W. G. et al.: Leridistim, a chimeric dual G-CSF and IL-3 receptor agonist, enhances multilineage hematopoietic recovery in a nonhuman primate model of radiation induced myelosuppression: effect of schedule, dose, and route of administration. Stem Cells, 2001, 19, s. 522–533.

16. Chang, Q., Harvey, K., Akard, L. et al.: Differences in CD34+ cell subpopulations between human bone marrow and “mobilized” peripheral blood as determined with counterflow centrifugal elutriation. Exp. Hematol., 1997, 25, s. 423–431.

17. Klabusay, M., Suková, V., Kořístek, Z. et al.: Analýza fenotypu a kinetiky subpopulací CD34⁺ buněk a lymfocytů dárců periferních hematopoetických kmenových buněk pro alogenní transplantace. Čas. Lék. čes., 2003, 142, s. 410–416.

18. Hassan, H. T., Stockschlader, M., Schleimer, B. et al.: Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors. Transpl. Immunol., 1996, 4, s. 319–323.

19. Mayer, J., Kořístek, Z., Pospíšil, Z. et al.: Kinetika obnovy krvetvorby po vysokodávkované chemoterapii a autologní transplantaci periferních kmenových buněk. Čas. Lék. čes., 1999, 138, s. 170–177.

20. Hashimoto, S., Itoh, M., Nishimura, M., Asai, T.: Effect of filgrastim administration for steady-state mobilization of peripheral blood stem cells. Ther Apher., 2002, 6, s. 431–436.

21. Nabholtz, J. M., Cantin, J., Chang, J. et al.: Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial. Clin. Breast Cancer, 2002, 3, s. 268–275.

Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management fenix.admin.empty
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account